02-27-02

∴ DOCKET NO. : AREN-0320

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Chen W. Liaw, Derek T. Chalmers, Dominic P. Behan, Dominique Maciejewski-Lenior, James N. Leonard, I-Lin Lin, and Daniel Ortuno

Serial No.: Not yet assigned

Group Art Unit: Not yet assigned

Filing Date: Herewith

Examiner: Not yet assigned

For: ENDOGENOUS AND NON-ENDOGENOUS VERSIONS OF HUMAN G

PROTEIN-COUPLED RECEPTORS

EXPRESS MAIL LABEL NO: EL884785038 US DATE OF DEPOSIT: February 26, 2002

EL884785038US

Box	☑ Patent Application☑ Sequence ☐ Design	The same and the transfer and the same and the transfer and the same a
	tant Commissioner for Patents ington, DC 20231	
Sir:		
	PATENT APPLICATION	ON TRANSMITTAL LETTER

Transmitted herewith for filing, please find

\boxtimes	A Utility Patent Application under 37 C.F.R. 1.53(b).
	It is a continuing application, as follows:

☐ continuation	divisional	Continuation-in-part of prior application number

A Design Patent Application (submitted in duplicate).

Request for Nonpublication is attached. П

100001

DOCKET	NO .	ADEN	0320
IN IL REI	INC.	ARRIV	

- 2 -

PATENT

Including the following:

	New or Re	or Revised Specification, including pages 1 to 84 containing:			
	⊠ _{Sp}	ecification			
	⊠ Cla	aims			
	⊠ Ab	ostract			
	□ Su	bstitute Specification, including Claims and Abstract.			
		The present application is a continuation application of Application No filed The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Since none of those amendments incorporate new matter into the parent application, the present revised Specification also does not include new matter.			
•		The present application is a continuation application of Application No filed, which in turn is a continuation-in-part of Application No filed The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Although the amendments in the parent C-I-P application may have incorporated new matter, since those are the only revisions included in the present application, the present application includes no new matter in relation to the parent application.			
	including matter has for such e	Fearlier application Serial NoFiled			
	to Related	ter the following amendment to the Specification under the Cross-Reference diagrams. Applications section (or create such a section): "This Application: ontinuation of is a divisional of claims benefit of U.S. provisional on Serial No			

	DOC	KET NO.: AREN-0320 - 3 -					
		Signed Statement attached deleting inventor(s) named in the prior application.					
		A Preliminary Amendment.					
	\boxtimes	21 Sheets of Formal Drawings.					
		Drawing view to publish:1					
		Petition to Accept Photographic Drawings.					
		Petition Fee					
The state of the s	\boxtimes	An ☐ Executed ☑ Unexecuted Declaration or Oath and Power of Attorney.					
		An Associate Power of Attorney.					
		An Executed Copy of Executed Assignment of the Invention to					
		A Recordation Form Cover Sheet.					
		Recordation Fee - \$40.00.					
-		The prior application is assigned of record to					
r		Priority is claimed under 35 U.S.C. § 119 of Patent Application No.					
		filed in (country).					
		A Certified Copy of each of the above applications for which priority is claimed:					
		is enclosed.					
		has been filed in prior application Serial No filed					
		Please enter the following amendment to the first sentence of the specification (or create such a sentence): "This application claims benefit of international application No, which was published under PCT Article 21(2) in English."					

n	OCKET	NO .	ADEN	0320
v	OCKEI	NU. :	ARCIN-	ひろをひ

- 4 -

PATENT

	\boxtimes	Applicant(s) by its/their undersigned attorney, claims small entity status under 37 C.F.R. §1.27 as:					
		an Independent Inventor					
		a Small Business Concern					
		a Nonprofit Organization.					
	\boxtimes	Diskette Containing DNA/Amino Acid Sequence Information.					
	\boxtimes	Statement to Support Submission of DNA/Amino Acid Sequence Information.					
-	\boxtimes	Sequence listing consisting of pages 1-97.					
•		The computer readable form in this application, is identical with that filed in Application Serial Number, filed, filed, in accordance with 37 CFR 1.821(e), please use the first-filed, last-filed or only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the originally-filed specification of the instant application, included in a separately filed preliminary amendment for incorporation into the specification.					
		 Information Disclosure Statement. □ Attached Form 1449. □ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith. 					
		A copy of Petition for Extension of Time as filed in the prior case.					
		Appended Material as follows:					

DOC	KET NO	O. : AREN-0	320	- 5 -			PA
X	Returr	Return Receipt Postcard (should be specifically itemized).					
	Other	as follows: _					
FEE (CALCUI	LATION:					
	calcul		g fee. (At l			of the prior app Ident claim mu	
	***	******	*****	SMAL	L ENTITY	NOT SM	ALL ENTIT
				RATE	FEE	RATE	FEI
DESIG	N APPLIC	CATION		\$165.00	\$	\$330.00	\$
UTILI	TY APPLI	CATIONS BASE	FEE	\$370.00	\$370	\$740.00	\$
CALC		CATION; ALL C AFTER ENTRY (
		No. Filed	No. Extra				
	OTAL LAIMS	36- 20 =	16	\$9 each	\$144	\$18 each	\$
	IDEP. LAIMS	18-3=	15	\$42 each	\$630	\$84 each	\$
		SENTATION OF IT CLAIM	MULTIPLE	\$140	\$	\$280	\$
ADDIT	TIONAL F	ILING FEE		*************************************	\$774		\$
TOTA	L FILING	FEE DUE		*******	\$1144	********	\$ \$
\boxtimes		eck is enclose				d C.11	
	refund	l any overpay	ment associ	iated with the	s communic	the following f cation or during set is provided	g the pend

The foregoing amount due. \boxtimes Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.

- Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).
- The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: February 26, 2002

Michael P. Straher Registration No. 38,325

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

©2001 WW

include new matter.

DOCKET NO.: AREN-0320 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re	Application of:	
Liaw e	t al.	
Serial	No.: Not Assigned	Group Art Unit: Not Assigned
Filing	Date: Herwith	Examiner: Not Assigned
For:	Endogenous and Non-Endogenous Receptors	Versions of Human G Protein-Coupled
Box Sec	ntent and Trademark Office quence, P.O. Box 2327 on, Virginia 22202	Express Mail #EL884785038US
STA		AND SUBMISSION IN ACCORDANCE 321 THROUGH 1.825
	•	e requirements of 37 C.F.R. §1.821(f), that the adable copies of the Sequence Listing, submitted and (e), respectively are the same.
\boxtimes	I hereby state that the submission filed	t in accordance with 37 CFR 81 821(a) does not

I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not

I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.

I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

Sequence Listing does (do) not include new matter.

DOCK	XET NO.: AREN-0320	- 2 -	PATENT
	•	stitute copy of the computer .825(d), contains identical d	readable form, submitted in ata to that originally filed.
Date:	February 26, 2002	aifute face	

Michael P. Straher Registration No. 38,325

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568, 3100

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2001 WW